Chair
Member
Chairman of the board
Financial expert
Audit Committee Position

Susannah Gray  

Susannah Gray served as the Chief Financial Officer of Royalty Pharma from January 2005 to December 2018. She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets’ high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a B.A. in social studies from Wesleyan University.

Chair

Anat Ashkenazi  

Anat Ashkenazi is the Senior Vice President and Chief Financial Officer of Eli Lilly, where she has worked for over nineteen years. Ms. Ashkenazi joined Eli Lilly in 2001 and has had a diverse career spanning financial, strategy and operations roles. Prior to her current position, Ms. Ashkenazi served in the role of Senior Vice President, Controller and Chief Financial Officer of Lilly Research Laboratories. She also held roles as the chief financial officer for a number of global divisions within Eli Lilly, including Oncology, Diabetes, Global Manufacturing & Quality and Research & Development. Ms. Ashkenazi holds an MBA from Tel Aviv University and a B.A. in economics and business administration from the Hebrew University.

Member

Jessica Hopfield, Ph.D.

Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She serves as an independent director on the Board of Directors of Insulet Corporation, Editas Medicine and Radius Health. In addition, she is a strategic advisor and investor in start-up healthcare firms. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice where she led work in strategy, research and development management, and marketing across pharmaceutical, biotechnology and medical device industries. She also held management positions at Merck Sharp & Dohme in clinical development, outcomes research, and marketing. Dr. Hopfield holds a Ph.D. in biological sciences from The Rockefeller University, an MBA from Harvard Business School and a B.S. in biology from Yale College.

Member

Audit Committee Charter

Download
Compensation and Leadership Development Committee Position

Anat Ashkenazi  

Anat Ashkenazi is the Senior Vice President and Chief Financial Officer of Eli Lilly, where she has worked for over nineteen years. Ms. Ashkenazi joined Eli Lilly in 2001 and has had a diverse career spanning financial, strategy and operations roles. Prior to her current position, Ms. Ashkenazi served in the role of Senior Vice President, Controller and Chief Financial Officer of Lilly Research Laboratories. She also held roles as the chief financial officer for a number of global divisions within Eli Lilly, including Oncology, Diabetes, Global Manufacturing & Quality and Research & Development. Ms. Ashkenazi holds an MBA from Tel Aviv University and a B.A. in economics and business administration from the Hebrew University.

Chair

Susannah Gray  

Susannah Gray served as the Chief Financial Officer of Royalty Pharma from January 2005 to December 2018. She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets’ high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a B.A. in social studies from Wesleyan University.

Member

Constantine Mihas

Constantine Mihas has served as a member Maravai LifeSciences’s board since March 2016. Mr. Mihas joined GTCR in 2001 where he is currently a Managing Director and head of the Healthcare group. Prior to joining GTCR, Mr. Mihas was Chief Executive Officer and co-founder of Delray Farms, a specialty food retailer. Prior to Delray Farms, Mr. Mihas was with McKinsey & Company. Mr. Mihas holds an MBA with distinction from the Harvard Business School and a B.S. in finance and economics from the University of Illinois, Chicago.

Member

Compensation and Leadership Development Committee Charter

Download
Nominating, Governance and Risk Committee Position

Jessica Hopfield, Ph.D.

Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She serves as an independent director on the Board of Directors of Insulet Corporation, Editas Medicine and Radius Health. In addition, she is a strategic advisor and investor in start-up healthcare firms. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice where she led work in strategy, research and development management, and marketing across pharmaceutical, biotechnology and medical device industries. She also held management positions at Merck Sharp & Dohme in clinical development, outcomes research, and marketing. Dr. Hopfield holds a Ph.D. in biological sciences from The Rockefeller University, an MBA from Harvard Business School and a B.S. in biology from Yale College.

Chair

Sean Cunningham

Sean Cunningham has served as a member of Maravai LifeSciences’s board since March 2016. Mr. Cunningham joined GTCR in 2001 where he is currently a Managing Director. He was previously a consultant with The Boston Consulting Group. Mr. Cunningham holds an MBA from the Wharton School at the University of Pennsylvania as well as a B.A. and B.E. in engineering sciences from Dartmouth College.

Member

Murali K. Prahalad, Ph.D

Murali K. Prahalad has served as a member Maravai LifeSciences’s board since August 2016. Dr. Prahalad is currently the President and Chief Executive Officer of Iridia, a nanotechnology company, and was most recently the President and Chief Executive Officer of Epic Sciences, a medical diagnostics company, from August 2013 through April 2019. Dr. Prahalad has two decades of experience in the technology and life science industries. From 2007 through 2013, Dr. Prahalad served in multiple roles at Life Technologies, including as Vice President of Corporate Strategy. Before Life Technologies, Dr. Prahalad was Vice President of Business Development at Sequenom. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology as well as an M.S. in medical sciences from Harvard University. He also holds a B.S. in cellular and molecular biology and economics from the University of Michigan.

Member

Nominating, Governance and Risk Committee Charter

Download

Susannah Gray

Susannah Gray served as the Chief Financial Officer of Royalty Pharma from January 2005 to December 2018. She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets’ high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a B.A. in social studies from Wesleyan University.

Anat Ashkenazi

Anat Ashkenazi is the Senior Vice President and Chief Financial Officer of Eli Lilly, where she has worked for over nineteen years. Ms. Ashkenazi joined Eli Lilly in 2001 and has had a diverse career spanning financial, strategy and operations roles. Prior to her current position, Ms. Ashkenazi served in the role of Senior Vice President, Controller and Chief Financial Officer of Lilly Research Laboratories. She also held roles as the chief financial officer for a number of global divisions within Eli Lilly, including Oncology, Diabetes, Global Manufacturing & Quality and Research & Development. Ms. Ashkenazi holds an MBA from Tel Aviv University and a B.A. in economics and business administration from the Hebrew University.

Jessica Hopfield, Ph.D.

Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She serves as an independent director on the Board of Directors of Insulet Corporation, Editas Medicine and Radius Health. In addition, she is a strategic advisor and investor in start-up healthcare firms. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice where she led work in strategy, research and development management, and marketing across pharmaceutical, biotechnology and medical device industries. She also held management positions at Merck Sharp & Dohme in clinical development, outcomes research, and marketing. Dr. Hopfield holds a Ph.D. in biological sciences from The Rockefeller University, an MBA from Harvard Business School and a B.S. in biology from Yale College.

Anat Ashkenazi

Anat Ashkenazi is the Senior Vice President and Chief Financial Officer of Eli Lilly, where she has worked for over nineteen years. Ms. Ashkenazi joined Eli Lilly in 2001 and has had a diverse career spanning financial, strategy and operations roles. Prior to her current position, Ms. Ashkenazi served in the role of Senior Vice President, Controller and Chief Financial Officer of Lilly Research Laboratories. She also held roles as the chief financial officer for a number of global divisions within Eli Lilly, including Oncology, Diabetes, Global Manufacturing & Quality and Research & Development. Ms. Ashkenazi holds an MBA from Tel Aviv University and a B.A. in economics and business administration from the Hebrew University.

Susannah Gray

Susannah Gray served as the Chief Financial Officer of Royalty Pharma from January 2005 to December 2018. She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets’ high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a B.A. in social studies from Wesleyan University.

Constantine Mihas

Constantine Mihas has served as a member Maravai LifeSciences’s board since March 2016. Mr. Mihas joined GTCR in 2001 where he is currently a Managing Director and head of the Healthcare group. Prior to joining GTCR, Mr. Mihas was Chief Executive Officer and co-founder of Delray Farms, a specialty food retailer. Prior to Delray Farms, Mr. Mihas was with McKinsey & Company. Mr. Mihas holds an MBA with distinction from the Harvard Business School and a B.S. in finance and economics from the University of Illinois, Chicago.

Jessica Hopfield, Ph.D.

Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She serves as an independent director on the Board of Directors of Insulet Corporation, Editas Medicine and Radius Health. In addition, she is a strategic advisor and investor in start-up healthcare firms. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice where she led work in strategy, research and development management, and marketing across pharmaceutical, biotechnology and medical device industries. She also held management positions at Merck Sharp & Dohme in clinical development, outcomes research, and marketing. Dr. Hopfield holds a Ph.D. in biological sciences from The Rockefeller University, an MBA from Harvard Business School and a B.S. in biology from Yale College.

Sean Cunningham

Sean Cunningham has served as a member of Maravai LifeSciences’s board since March 2016. Mr. Cunningham joined GTCR in 2001 where he is currently a Managing Director. He was previously a consultant with The Boston Consulting Group. Mr. Cunningham holds an MBA from the Wharton School at the University of Pennsylvania as well as a B.A. and B.E. in engineering sciences from Dartmouth College.

Murali K. Prahalad, Ph.D

Murali K. Prahalad has served as a member Maravai LifeSciences’s board since August 2016. Dr. Prahalad is currently the President and Chief Executive Officer of Iridia, a nanotechnology company, and was most recently the President and Chief Executive Officer of Epic Sciences, a medical diagnostics company, from August 2013 through April 2019. Dr. Prahalad has two decades of experience in the technology and life science industries. From 2007 through 2013, Dr. Prahalad served in multiple roles at Life Technologies, including as Vice President of Corporate Strategy. Before Life Technologies, Dr. Prahalad was Vice President of Business Development at Sequenom. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology as well as an M.S. in medical sciences from Harvard University. He also holds a B.S. in cellular and molecular biology and economics from the University of Michigan.